Tech Company Financing Transactions

Virdante Pharmaceuticals Funding Round

Thomas, McNerny & Partners, Biogen Idec and Clarus participated in a $47.8 million funding round for Virdante Pharmaceuticals. The round was announced on 10/29/2009.

Transaction Overview

Company Name
Virdante Pharmaceuticals
Announced On
10/29/2009
Transaction Type
Venture Equity
Amount
$47,750,000
Round
Undisclosed
Investors

Thomas, McNerny & Partners (Lead Investor) (Eric Aguiar)

Biogen Idec

Clarus (Michael Steinmetz)

MedImmune Ventures (Gail Wasserman)

Osage Partners

Venrock (Anders Hove)

Proceeds Purpose
Virdante also announced today that the Company plans to use the proceeds from the new financing to pursue development of a second drug, a sialylated recombinant IgG Fc fragment ("sFc"), the segment of IgG responsible for the anti-inflammatory activity of IVIG. In addition, Virdante plans to expand the application of its Sialic Switch technology to improve the potency of important anti-inflammatory antibodies such as anti-TNF drugs.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
14 Cambridge Center Bldg 1
Cambridge, MA 02142
USA
Phone
(617) 300-8500
Website
www.virdante.com
Email Address
[email protected]
Overview
Virdante is a privately held biopharmaceutical company focused on the development and commercialization of drugs for autoimmune and inflammatory disorders.
Profile
Virdante Pharmaceuticals LinkedIn Company Profile
Social Media
Virdante Pharmaceuticals Company Twitter Account
Company News
Virdante Pharmaceuticals News
Facebook
Virdante Pharmaceuticals on Facebook
YouTube
Virdante Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chairman
Pat Gage
  Pat Gage LinkedIn Profile  Pat Gage Twitter Account  Pat Gage News  Pat Gage on Facebook
Chief Executive Officer
John Ripple
  John Ripple LinkedIn Profile  John Ripple Twitter Account  John Ripple News  John Ripple on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/29/2009: Data Robotics venture capital transaction
Next: 10/30/2009: Mytrus venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.